Vir Biotechnology Inc (VIR)
Receivables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 74,205 | 86,180 | 1,580,470 | 1,087,070 | 76,368 |
Receivables | US$ in thousands | — | — | — | — | — |
Receivables turnover | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $74,205K ÷ $—K
= —
The receivables turnover ratio for Vir Biotechnology Inc for the years 2020, 2021, 2022, 2023, and 2024 is indicated as "—". This suggests that specific data on accounts receivable turnover is not available or not applicable. As a result, we are unable to assess the efficiency of the company in collecting its receivables during these periods. It is essential for the company to provide more detailed information or context to further analyze and understand its receivables turnover performance in the future.
Peer comparison
Dec 31, 2024
Company name
Symbol
Receivables turnover
Vir Biotechnology Inc
VIR
—
ADMA Biologics Inc
ADMA
8.53
Amgen Inc
AMGN
—
Bio-Techne Corp
TECH
4.80
Biogen Inc
BIIB
6.89
Gilead Sciences Inc
GILD
—
Halozyme Therapeutics Inc
HALO
—
Krystal Biotech Inc
KRYS
2.83
Moderna Inc
MRNA
—
Neurocrine Biosciences Inc
NBIX
4.77
Repligen Corporation
RGEN
—